left
Hey There : )
right
company-image

Unlisted Shares

Healthcaps India Ltd. Essentials

As of July 27, 2024, Healthcaps India Ltd., Unlisted Shares are trading at ₹180.00 per share, with a 52-week high of ₹180 and 52-week low of ₹180. The minimun lot size is 1115 shares, and the shares are traded on NSDL and CDSL.

ISIN

INE936K01016

Face Value

₹ 10

Total Share

40,37,190

Total Income

₹ 246.36 undefined

Profit After Tax

₹ ****

EPS

₹ ****

P/E

****

P/B

****

Market Capitalisation

₹ 72.67 Cr

Enterprise Value

₹ ****

Book Value

₹ 368.12

Intrinsic Value

₹ ****

Earnings Yield

41.03 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Delisted

Cashflow - Operations

20.4

Cashflow - Financing

0.84

Healthcaps India Ltd. Growth

Compounded Sales Growth

1 Year

3 Year

7 Year

Compounded Profit Growth

1 Year

3 Year

7 Year

Return On Equity

2017

2020

2023

Highlights

image
  • Leader in Empty Capsule Manufacturing - HealthCaps India Ltd ("HIL") has been manufacturing Empty Hard Gelatin Capsule Shells for over two decades. These capsules are widely used to encapsulate drugs, vitamins, antibiotics, etc. It also manufactures BSE/TSE-free EHG Capsules using EDQM-approved gelatin. The installed capacity of Empty Hard Gelatin Capsule in India is 100 billion capsules per annum. Healthcaps India leads the market with an installed capacity of 19 billion capsules annually.
image
  • Revenue Growth - In FY22, the company saw a substantial increase due to COVID-19, whereas in FY3, the company's revenue experienced a subtle decrease, declining from ₹255 Cr in FY22 to ₹246 Cr in FY23, indicating a decline rate of -3.4%. Over the past five years, the company's revenue has substantially increased, achieving a compound annual growth rate (CAGR) of 24.6% from FY18 to FY23.
image
  • Profitability - The company's profitability has consistently improved over time. The EBIT margin, which was 13.2% in FY18, has risen to 15.9% in FY23, reflecting a compound annual growth rate (CAGR) of 3.9%. Likewise, the net profit margin of the company has increased from 8.1% in FY18 to 12.1% in FY23, demonstrating a CAGR of 8.4% from FY18 to FY23.
image
  • Investment Thesis - Healthcaps India holds the leading position with an installed capacity of 19 billion capsules annually. Listed competitors are trading at an average P/E ratio of 12.5x. With a discount for lack of marketability (DLOM) ranging from 30% to 50%, the anticipated share price for Healthcaps is projected to fall within the range of ₹450 to ₹650. Considering the current share price at ₹180, the stock is deemed undervalued, presenting investors with a compelling investment opportunity with potential returns ranging from 3x to 4x.
image
  • Share Cancellation - As of 21st July 2023, the company has 16,451 public shareholders holding 9,23,860 equity shares. The company has passed a special resolution to reduce the issued, subscribed, and paid-up equity share capital of the company from 40,37,190 equity shares of ₹10 each to 32,13,330 equity shares of ₹10 each by canceling and extinguishing 9,23,860 equity shares of ₹10 each, collectively held by the shareholders of the company by paying a sum of ₹273.58 per equity share, so canceled and extinguished. These shareholders are those who had not accepted exit at the time of delisting or have become shareholders through private dealings / off-market dealings amongst public shareholders.

Business Rating

image

Managment

lock starlock starlock starlock starlock star
image

Accounting Practice

lock starlock starlock starlock starlock star
image

Profatibility

lock starlock starlock starlock starlock star
image

Solvency

lock starlock starlock starlock starlock star
image

Growth

lock starlock starlock starlock starlock star
image

Valuation

lock starlock starlock starlock starlock star

Overall Ratings

lock starlock starlock starlock starlock star

Recommendation

lock starlock starlock starlock starlock star

Our Team

Quantity

Invest

, Min. Investment: ₹